Suzhou, Dec. 20, 2020--Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the company‘s shares have been included in FTSE Global Equity Index Series (“FTSE GEIS”) micro-cap index, with effective after the close of business on December 18. Kintor Pharma’s inclusion in the FTSE GEIS symbolises that the company has further expanded its influence in the international capital markets and will attract more attention from investors.

FTSE is the world’s second largest index agency, and FTSE GEIS covers over 16,000 securities from large to micro-cap across 49 developed and emerging countries globally. It is widely used by investment managers and institutional investors to target specific markets or market segments, and serves as a benchmark for investment strategies.

Along with Kintor Pharma’s shares being included in the FTSE GEIS index, the company will continue to deepen investment on R&D, clinical operations and prepare for the commercialization of core products, in this way to bring great returns for shareholders.